Last Updated on October 17, 2024 by The Health Master
Shilpa Medicare has received US Food and Drug Administration (USFDA) tentative approval for its ANDA, Apremilast Tablets, 10 mg, 20 mg, and 30 mg dated 04 Mar 2021.
The ANDA was filed as ‘First to File’ submission on NCE -1 date to seek eligibility for 180 days exclusivity.
Apremilast Tablets, 10 mg, 20 mg, and 30 mg is a generic equivalent of reference listed drug (RLD) OTEZLA of Celgene used in the treatment of ‘psoriatic arthritis’ as recommended in the label approved by FDA.
According to IQVIA MAT Q2 2020 data, the US market for Apremilast Tablets, 10 mg, 20 mg, and 30 mg is approximately $2.4 billion.
Also read:
Aleor Dermaceuticals gets USFDA nod for Testosterone Gel
Unichem gets USFDA nod for Guanfacine Tablets
Cipla gets US FDA approval for generic drug for Migraine
Lupin launches generic Penicillamine tablets
NATCO launches Epilepsy Tablets in India
ICPA launches antibiotic for Dental treatment
